CURRICULUM VITAE
October 2, 2008
R. Bart Sangal, M.D.
Clinical Neurophysiology Services, P.C.
44199 Dequindre, Ste. 311, Troy, MI 48085
CURRENT POSITION:
In private practice as Director of Sleep/Attention Disorders Institutes (Clinical Neurophysiology Services, P.C.), Beaumont Hospital Professional Building, Troy, Sep. 1986 - now.
Associate Professor (Clinical), Wayne State University School of Medicine, Detroit, 2006 – now.
EDUCATION:
· Delhi University, Delhi, India, Pre-Medical, 1972.
· All India Institute of Medical Sciences, New Delhi, India, M.B.,B.S., 1978
TRAINING:
· SUNY-Upstate Medical Center, Syracuse, NY, Internship in Medicine-Psychiatry, Jan 1979 -Dec 1979
· Johns Hopkins University Hospitals, Baltimore, MD, Residency in Psychiatry, Jan 1980 - Dec 1982
· NIH/Johns Hopkins, Baltimore, MD, Fellowship in Psychophysiology, July 1982 – June 1983
FACULTY APPOINTMENTS:
Wayne State University School of Medicine, Dept. of Psychiatry, Instructor 1984-1993, Assistant Professor 1993-2000, Associate Professor 2006-now.
LICENSURE AND BOARD CERTIFICATION
· Licensed in Michigan, Massachusetts, and California.
· Diplomate, Sleep Medicine, American Board of Psychiatry and Neurology, 2007.
· Certified Physician Investigator, Academy of Pharmaceutical Physicians & Investigators/ American College of Research Professionals, 2002.
· Diplomate, Clinical Neurophysiology, American Board of Psychiatry and Neurology, 1992.
· Diplomate, American Board of Sleep Medicine, 19985, with highest score in the nation in the Part I examinations.
· Diplomate, American Board of Psychiatry and Neurology, 1985, score 97% ile.
NATIONAL HONORS/AWARDS:
Awarded the Mark Hatfield Award for Public Policy by the American Academy of Sleep Medicine in 2006.
SERVICE:
1. Patient Care: Director of Sleep/Attention Disorders Institutes, Beaumont Hospital Professional Building, Troy, Sep 1986 - now. The Sleep Disorders Institute is accredited by the American Academy of Sleep Medicine. Before that, independent contractor with a group practice which no longer exists (PCM Clinic, Mt. Clemens, MI), July 1983 – Aug. 1986.
2. Professional Consultation: Director of Sangal Research Foundation, a non-profit foundation for education and research in Clinical Neurophysiology.
3. Journal/Editorial Activity: Member, Editorial Board, Clinical Electroencephalography, 1997-now.
4. National Boards and Committees:
· American Academy of Sleep Medicine:
Chair, The Business of Sleep Medicine Course, 2008 – now
Member, Board of Directors, 1996-1999
Co-Chair, Reimbursement Committee, 1991-1994
Member, Government Affairs Committee, 1992-1994
· American Medical Association:
Delegate to Hospital Medical Staff Section from Beaumont Hosp., Troy, 1992-now
· Electroencephalography and Clinical Neuroscience Society
5. State and local boards and committees:
· Michigan Sleep Disorders Association:
Director, 2007 - now
Chair, Standards of Practice Committee, 1990-now
President, 1989-90
· Michigan State Medical Society
Member, Third Party Payer Liaison Committee, 1994-2006
Member, Blue Cross-Blue Shield Liaison Committee, 1989-1994
Alternate Delegate to MSMS Young Physicians Section from OCMS, 1988-90
· Member, Oakland County Medical Society
Member, Legislation Committee, 1988-2002; 2007-now
Member, Bulletin Committee, 1988-1998; 2007-now
Member, Public Information Committee, 1988-89
TEACHING:
Wayne State University School of Medicine: 1984-2000. Offered Sleep Medicine/ Clinical Neurophysiology elective rotation to medical students and residents at Wayne State University School of Medicine.
Beaumont/ Wayne State University/ U of M: Lectures to rotating medical students
CLINICAL RESEARCH STUDIES/GRANT SUPPORT:
1. A Nine Week Placebo-Controlled, Double-Blind, Randomized, Parallel-group study of the efficacy of two fixed doses (200 mg, 400 mg) of oral Modafinil in patients with Narcolepsy; followed by An 40 week, open-label, flexible-dose continuation study, followed by recurrent 48 week open-label extensions; 1994-1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
2. Cognex: Neuropsychiatric Testing and Assessment of Caregiver Time Study; 1996. Principal Investigator: R. Bart Sangal, M.D. Supported by Parke-Davis Medical Research.
3. A Double-Blind Flexible Dose Study of Transdermal Buspirone in the Treatment of Children with Attention-Deficit Hyperactivity Disorder; 1997-1998. Principal Investigator: R. Bart Sangal, M.D. Supported by Bristol-Myers Squibb Co.
4. A Double-Blind Fixed Dose Study of Transdermal Buspirone in the Treatment of Children with Attention-Deficit Hyperactivity Disorder; followed by An Open-Label, Long Term, Flexible Dose Safety Study of Transdermal Buspirone in the Treatment of Childhood Attention-Deficit Hyperactivity Disorder; 1998. Principal Investigator: R. Bart Sangal, M.D. Supported by Bristol-Myers Squibb Co.
5. An Open-Label, Long Term, Flexible Dose Safety Study of Transdermal Buspirone in the Treatment of Childhood Attention-Deficit Hyperactivity Disorder; 1997-1998. Principal Investigator: R. Bart Sangal, M.D. Supported by Bristol-Myers Squibb Co.
6. The Pharmacokinetics of Buspirone during Transdermal Administration to Children with Attention-Deficit Hyperactivity Disorder, with and without RitalinR Therapy; 1998. Principal Investigator: R. Bart Sangal, M.D. Supported by Bristol-Myers Squibb Co.
7. A Six-Week Open-Label Study of Safety and Efficacy of ProvigilR (Modafinil) in patients switching from stimulant therapy for Narcolepsy-associated Excessive Daytime Sleepiness; 1998-1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
8. A Double-Blind, Randomized, Parallel-Design, Placebo-Controlled Trial of d-threo-Methylphenidate Hydrochloride (d-MPH) and dl-threo-Methylphenidate Hydrochloride (dl-MPH) in Children with Attention Deficit Hyperactivity Disorder (ADHD); 1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Celgene Corporation.
9. A Double-Blind, Randomized, Parallel-Design, Placebo-Controlled Withdrawal Trial of d-threo-Methylphenidate Hydrochloride (d-MPH) in Children with Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responding to d-MPH; 1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Celgene Corporation.
10. A Six Month Open-Label Safety Trial of d-threo-Methylphenidate Hydrochloride (d-MPH) in Children with Symptoms of Attention Deficit Hyperactivity Disorder (ADHD); 1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Celgene Corporation.
11. A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study evaluating the efficacy and safety of Buspirone Hydrochloride (15-60 mg/day) in Children and Adolescents (aged 6 to 17) with Generalized Anxiety Disorder; 1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Bristol-Myers Squibb Co.
12. A Double-Blind, Placebo-Controlled, Multi-Center, Randomized, Parallel-Group study of the effect of four weeks of Provigil (Modafinil) treatment on Excessive Daytime Sleepiness in Obstructive Sleep Apnea Patients treated with Nasal Continuous Positive Airway Pressure; 1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
13. A Double-Blind, Placebo-Controlled Study of Modified Release (MR) Methylphenidate in Children with ADHD; 1999. Principal Investigator: R. Bart Sangal, M.D. Supported by Medeva Development.
14. A Phase III Open-Label Safety and Efficacy Study of Tomoxetine Hydrochloride in Outpatients with ADHD, Ages 6 to 18 years; 2000-2002. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
15. A Phase III Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges (mg/kg/day) of Tomoxetine with Placebo in Child and Adolescent Outpatients with ADHD, Aged 8 to 18 years; 2000-2002. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
16. A Multicenter, double-blind, randomized, placebo-controlled, parallel-group, evaluation of the safety and efficacy of a modified-release oral dosage form of Methylphenidate-HCl (Ritalin-QD) in children with ADHD; 2000. Principal Investigator: R. Bart Sangal, M.D. Supported by Novartis Pharmaceuticals Corporation.
17. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group study to evaluate the Safety and Efficacy of 12 weeks of 2 Oral Doses (200 mg and 400 mg once daily) of Provigil (Modafinil) as Treatment for Adults with Excessive Daytime Sleepiness associated with Obstructive Sleep Apnea/Hypopnea Syndrome followed by a 9-month open-label extension; 2000-2001. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
18. An Efficacy, Safety and Tolerability Study of (S)-Zopiclone in subjects with Transient Insomnia (First Night Effect Model); 2000-2001. Principal Investigator: R. Bart Sangal, M.D. Supported by Sepracor, Inc.
19. A Phase III Randomized, Double-Blind Comparison of Placebo and Tomoxetine in Adult Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder; 2000-2001. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
20. A Long-Term, Open Label, safety study of Tomoxetine Hydrochloride in Patients, 6 Years and Older; 2000-current. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
21. A Randomized, Double-Blind, Placebo-Controlled, Single Dose First Night Effect Sleep Laboratory Study of Two Doses of TAK-375 in Health Adult Volunteers; 2000. Principal Investigator: R. Bart Sangal, M.D. Supported by Takeda America Research and Development Center, Inc.
22. A Phase 3 Open-Label Safety and Efficacy Study of Tomoxetine Hydrochloride in Pediatric Outpatients (6 to 18 years) with ADHD; 2001. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
23. A Long-Term, Open Label, safety study of Tomoxetine Hydrochloride in Adult Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder; 2001-2007. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
24. Efficacy, Tolerability, and Safety of Once-Daily Tomoxetine Hydrochloride versus Placebo in Children with Attention-Deficit/Hyperactivity Disorder; 2001. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
25. Sleep and Cognitive/Neuropsychological Function in Children with Attention-Deficit/Hyperactivity Disorder Before and During Treatment with Tomoxetine Hydrochloride and Stimulants; 2001-2002. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
26. A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to assess the efficacy and safety of NBI-34060 in Elderly Patients with Chronic Insomnia, 2001. Principal Investigator: R. Bart Sangal, M.D. Supported by Neurocrine Biosciences, Inc.
27. A Randomized, Double-Blind Comparison of Atomoxetine Hydrochloride, Extended-Release Methylphenidate Hydrochloride (Concerta), and Placebo in Pediatric Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder, 2002-2003. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
28. Comparison of efficacy and safety of Zolpidem_MR 12.5 mg and placebo in patients with primary insomnia. A double-blind, randomized, placebo-controlled, parallel-group study, 2002. Principal Investigator: R. Bart Sangal, M.D. Supported by Sanofi-Synthelabo.
29. A Double-Blind Study of Treatment Optimization with Atomoxetine Hydrochloride in Adults with DSM-IV Attention-Deficit/Hyperactivity Disorder, 2002-2003. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
30. A Randomized, Double-Blind, Active- and Placebo-Controlled 4-Way Crossover Study of the Safety and Efficacy of PD 0200390, Zolpidem, and Placebo in Primary Insomnia, 2002. Principal Investigator: R. Bart Sangal, M.D. Supported by Pfizer, Inc.
31. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Safety and Efficacy of TAK-375 in Elderly Subjects with Chronic Insomnia, 2002-2003. Principal Investigator: R. Bart Sangal, M.D. Supported by Takeda Pharmaceuticals.
32. A Phase III, Randomized, Double-Blind, Placebo-Controlled, PSG Plus Outpatient Study to Determine the Safety and Efficacy of TAK-375 in Adults with Chronic Insomnia, 2003. Principal Investigator: R. Bart Sangal, M.D. Supported by Takeda Pharmaceuticals.
33. A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects with Chronic Insomnia, 2003-2004. Principal Investigator: R. Bart Sangal, M.D.,Supported by Takeda Pharmaceuticals.
34. A 5-week, multicenter, double-blind, randomized, placebo-controlled, fixed-dose study of the efficacy and safety of FocalinTM LA (dexmethylphenidate hydrochloride extended-release capsules) administered once daily in adults with Attention-Deficit/Hyperactivity Disorder, 2003. Principal Investigator: R. Bart Sangal, M.D. Supported by Novartis Pharmaceuticals.
35. A 6-month, open-label extension to a 5-week, multicenter, double-blind, randomized, placebo-controlled, fixed-dose study of the efficacy and safety of FocalinTM LA (dexmethylphenidate hydrochloride extended-release capsules) administered once daily in adults with Attention-Deficit/Hyperactivity Disorder, 2003. Principal Investigator: R. Bart Sangal, M.D. Supported by Novartis Pharmaceuticals.
36. A 9-week, randomized, double-blind, placebo-controlled, flexible-dosage (up to 425 mg/day), parallel-group study to evaluate the efficacy and safety of Modafinil (Film-coated Tablet) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, 2004. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
37. A 1-year, open-label, flexible-dosage study to evaluate the safety and continued efficacy of modafinil (Film-coated Tablet) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, 2004-2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
38. A double-blind study of functional outcomes with Atomoxetine-Hydrochloride and Placebo in adult outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder, 2004-2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
39. A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of Gabitril (4, 6, 8, and 10 mg) treatment in adult patients with primary insomnia, 2004. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
40. A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of Gabitril (2, 4, 6, and 8 mg) treatment in elderly patients with primary insomnia, 2004. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
41. A 12-month, open-label study to evaluate the safety and efficacy of Gabitril at dosages up to 10 mg/day in adults with primary insomnia, 2004. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
42. A 12-month, open-label study to evaluate the safety and efficacy of Gabitril at dosages up to 8 mg/day in elderly adults with primary insomnia, 2004-2005. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
43. A North American, 4-week, multicenter, phase IIB double-blind, placebo-controlled, randomized, multiple dose, parallel-group study of the efficacy and safety of 0.5 mg, 1.0 mg and 2.0 mg M100907 tablets in the treatment of sleep maintenance insomnia, 2004-2005. Principal Investigator: R. Bart Sangal, M.D. Supported by Aventis, Inc.
44. Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults with ADHD Over and Extended Period of Time (6 Months): With a Brief Evaluation of Executive Cognition, 2004-2005. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
45. An Exploratory Open-Label Safety and Efficacy Study of Atomoxetine in the Treatment of Mild Obstructive Sleep Apnea, 2004-2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
46. A randomized, 4-way cross-over, double-blind, placebo-controlled, multicenter dose-finding trial with three dosages of Org 50081 in patients with Primary Insomnia, 2004-2005. Principal Investigator: R. Bart Sangal, M.D. Supported by Organon.
47. A double-blind, randomized, placebo-controlled, multicenter, 30-night polysomnographic study of MK-0928 in Elderly patients with Primary Insomnia, 2005-2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Merck & Co., Inc.
48. A double-blind, randomized, placebo-controlled, multicenter, 30-night polysomnographic study of MK-0928 in Adult patients with Primary Insomnia, 2005-2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Merck & Co., Inc.
49. A Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to assess the long term efficacy and safety of doxepin HCl in Primary Elderly Insomnia patients with sleep maintenance difficulties, 2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Somaxon Pharmaceuticals, Inc.
50. Efficacy, safety and tolerability of zolpidem in the treatment of children aged 6 to 17 years with ADHD-associated insomnia. A multicentre, randomized, double-blind, placebo-controlled study, 2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Sanofi-Aventis.
51. A 6-week, double-blind, placebo-controlled, parallel-group randomized-withdrawal study to evaluate the continued efficacy of modafinil treatment at dosages up to 425 mg/day in patients with Attention-Deficit/Hyperactivity Disorder who are responders to modafinil treatment, followed by a 12-month open-label extension period, 2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Cephalon, Inc.
52. A 28 day, polysomnographic and subjective assessment of GW679769, 10 and 30 mg, for the treatment of Primary Insomnia: A randomized, double-blind, parallel-group, placebo-controlled trial, 2006. Principal Investigator: R. Bart Sangal, M.D. Supported by Glaxo-Smith-Kline.
53. A Randomized, double-blind comparison of placebo and atomoxetine hydrochloride given once a day in adults with Attention-Deficit/Hyperactivity Disorder: with a secondary examination of impact of treatment on family functioning, 2006-2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
54. A Multi-Center, Randomized, Double-blind, Parallel Study of The Efficacy and Safety of Two Weeks of Dosing of Various Formulations and Doses of NG2-73 and Placebo for Sleep Initiation in Primary Insomniacs, 2006-2007. Principal Investigator: R. Bart Sangal, M.D. Supported by Neurogen.
55. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging study of the safety and efficacy of ABT-894 in adults with Attention Deficit-Hyperactivity Disorder (ADHD), 2007. Principal Investigator: R. Bart Sangal, M.D. Supported by Abbott.
56. A Six-week, double-blind, randomized, placebo-controlled, parallel group, efficacy and safety, sleep lab trial with Org 50081 in patients with chronic primary insomnia, 2007. Principal Investigator: R. Bart Sangal, M.D. Supported by Organon.
57. Fifty-two weeks, open-label extension trial to evaluate safety and efficacy of Org 50081 in outpatients with chronic primary insomnia who completed Clinical Trial Protocol 176001 or 176002, 2007-2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Organon.
58. A Phase II1, randomized, double-blind, placebo-controlled, incomplete-block, two-period crossover clinical trial to study the safety and efficacy of MK-0249 for adult patients, ages 18 to 55, with Attention Deficit Hyperactivity Disorder (ADHD), 2007-2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Merck.
59. A prospective, open-label, multi-center, dose-optimization study evaluating the efficacy, safety and tolerability of Vyvanse 20-70 mg in children aged 6-12 diagnosed with ADHD, 2007-2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Shire.
60. A phase IIIb, randomized, double-blind, multi-center, parallel-group, placebo-controlled, dose optimization study, designed to evaluate the efficacy and safety of methylphenidate transdermal system (MTS) in adolescents aged 13-17 years with attention-deficit/hyperactivity disorder (ADHD), 2007-2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Shire.
61. A Multicenter, randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of VEC-162 (20 mg/day and 50 mg/day) in the treatment of primary insomnia, 2007-2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Vanda.
62. A Pilot, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 study of the safety, tolerability and efficacy of 0.7 mg/kg/day and 1.4 mg/kg/day ABT-089 in the treatment of children with Attention-Deficit/Hyperactivity Disorder (ADHD), 2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Abbott.
63. A Pilot, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 study of the safety, tolerability and efficacy of 40 mg qd and 80 mg qd ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD), 2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Abbott.
64. The long-term safety and tolerability of ABT-089 in children with Attention-Deficit/Hyperactivity Disorder (ADHD): an open-label extension study, 2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Abbott.
65. The long-term safety and tolerability of ABT-089 in children with Attention-Deficit/Hyperactivity Disorder (ADHD): an open-label extension study for subjects completing study M10-346, 2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Abbott.
66. A phase III, randomized, double-blind, multi-center, parallel group, placebo-contolled, forced-dose titration, safety and efficacy study of lisdexamfetamine dimesylate (LDX) in adolescents aged 13-17 with attention-deficit/hyperactivity disorder (ADHD), 2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Shire.
67. A phase III, open-label, extension, multi-center, safety and efficacy study of lisdexamfetamine dimesylate (LDX) in adolescents aged 13-17 with attention-deficit/hyperactivity disorder (ADHD), 2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Shire.
68. A phase 2, randomized, double-blind, placeo- and active-comparator-controlled study of the safety and efficacy of LY2624803 in outpatients with insomnia, 2008. Principal Investigator: R. Bart Sangal, M.D. Supported by Lilly.
PUBLICATIONS
Original observations in refereed journals:
1. Sangal R. Medical Profession and the Population Problem in the Student as Future Physician Perspective. The Indian Journal of Medical Education, 13:185-186, 1974.
2. Sangal R. Rotating Intern's Images of Practitioners of Five Medical Specialties. J. Med. Educ., 54:500-502, 1979.
3. Sangal R, Coyle G, Hoehn-Saric R. Chronic Anxiety and Social Adjustment. Comprehensive Psychiatry, 24:75-78, 1983.
4. Sangal R, Correa EI, DePaulo R. Depression and Anxiety Inventories, and the Dexamethasone Suppression Test. Biological Psychiatry, 19:1207-1213, 1984.
5. Sangal R, Dimitrijevic R. Neuroleptic Malignant Syndrome: Successful Treatment with Pancuronium. JAMA, 254:2795-2796, 1985. Translated into the French, Italian and Japanese editions.
6. Sangal R. Electroconvulsive Treatment: A Rose is a Rose (Editorial). Biological Psychiatry, 21:709, 1986.
7. Sangal RB, Thomas L, Mitler MM. The Maintenance of Wakefulness Test (MWT) and the Multiple Sleep Latency Test (MSLT) measure different abilities in patients with sleep disorders. Chest, 101:898-902, 1992.
8. Sangal RB, Thomas L, Mitler MM. Disorders of Excessive Sleepiness: Treatment Improves Ability to Stay Awake but Does Not Reduce Sleepiness. Chest, 102:699-703, 1992.
9. Sangal RB, Sangal JM. P300 Latency: Abnormal in Sleep Apnea with Somnolence and Idiopathic Hypersomnia, but Normal in Narcolepsy. Clinical Electroencephalography, 26:146-153, 1995.
10. Sangal JM, Sangal RB, Persky B. Abnormal Auditory P300 Topography in Attention Deficit Disorder predicts Poor Response to Pemoline. Clinical Electroencephalography, 26:204-213, 1995.
11. Sangal RB, Sangal JM. Topography of Auditory and Visual P300 in Normal Children. Clinical Electroencephalography, 27:46-51, 1996.
12. Sangal RB, Sangal JM. Closed Head Injury Patients with Mild Cognitive Complaints without Neurological or Psychiatric Findings have abnormal Visual P300 Latencies. Biological Psychiatry, 39:305-307, 1996.
13. Sangal RB, Sangal JM. Topography of Auditory and Visual P300 in Normal Adults. Clinical Electroencephalography, 27:145-150, 1996.
14. Sangal JM, Sangal RB, Persky B. Prolonged P300 Latency in Attention Deficit Hyperactivity Disorder predicts poor response to Imipramine. Clinical Electroencephalography, 27:191-201, 1996.
15. Sangal RB, Sangal JM. Obstructive Sleep Apnea and Abnormal P300 Latency Topography. Clinical Electroencephalography, 28:16-25, 1997.
16. Sangal RB, Semery J-P, Belisle CL. Computerized Scoring of Abnormal Human Sleep: A Validation. Clinical Electroencephalography, 28: 64-67, 1997.
17. Sangal RB, Sangal JM. Measurement of P300 and Sleep Characteristics in Patients with Hypersomnia: Do P300 Latencies, P300 Amplitudes and Multiple Sleep Latency and Maintenance of Wakefulness Tests measure different Factors? Clinical Electroencephalography, 28:179-184, 1997.
18. Chesson AL, Ferber RA, Fry JM, Grigg-Damberger M, Hartse KM, Hurwitz TD, Johnson S, Kader GA, Littner M, Rosen G, Sangal RB, Schmidt-Nowara W, Sher A. The Indications for Polysomnography and Related Procedures. Sleep, 20:423-487, 1997.
19. Sangal RB, Sangal JM. Abnormal Visual P300 Latency in Obstructive Sleep Apnea does not Change Acutely upon Treatment with CPAP. Sleep, 20:702-704, 1997.
20. Doghramji K, Mitler MM, Sangal RB, et al. A Normative Study of the Maintenance of Wakefulness Test (MWT). Electroencephalography and Clinical Neurophysiology, 103:554-562, 1997.
21. US Modafinil in Narcolepsy Multicenter Study Group (incl. Sangal RB., Sangal JM, Belisle C, et al.). Randomized Trial of Modafinil for the Treatment of Pathological Somnolence in Narcolepsy. Ann Neurol, 43:88-97, 1998.
22. Sangal RB, Sangal JM. P300 Latency and Age: A Quadratic Regression explains their Relationship from Age 5 to 85. Clinical Electroencephalography, 29:1-6, 1998.
23. Sangal RB. Conclusions from Brain Mapping: Need for Statistical Rigor (Guest Editorial). Clinical Electroencephalography, 29:V, 1998.
24. Mitler MM, Walsleben J, Sangal RB, Hirshkowitz M. Sleep latency on the maintenance of wakefulness test (MWT) for 530 patients with narcolepsy while free of psychoactive drugs. Electroencephalography and Clinical Neurophysiology, 107:33-38, 1998.
25. Sangal RB, Sangal JM, Belisle C. Longer Auditory and Visual P300 Latencies in Patients with Narcolepsy. Clinical Electroencephalography, 30:28-32, 1999.
26. Sangal RB, Sangal JM, Belisle C. Subjective and Objective Indices of Sleepiness (ESS and MWT) are not equally useful in patients with Sleep Apnea. Clin Electroencephalography, 30:73-75, 1999.
27. Sangal RB, Sangal JM, Belisle C. Visual P300 Latency Predicts Treatment Response to Modafinil in Patients with Narcolepsy. Clin Neurophysiology, 110:1041-1047, 1999.
28. Sangal RB Mitler MM, Sangal JM. Subjective Sleepiness Ratings (Epworth Sleepiness Scale) do not reflect the same Parameter of Sleepiness as Objective Sleepiness (Maintenance of Wakefulness Test) in patients with Narcolepsy. Clin Neurophysiology, 110:2131-2135, 1999.
29. Michelson D, Allen AJ, Busner C, Casat C, Dunn D, Kratochvil C., Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901, 2002.
30. Sangal RB, Sangal JM. What is a Significant Response in Drug Studies of Attention Deficit/Hyperactivity Disorder: Statistical Significance is Necessary, but is it Sufficient? Psychopharmacology Bulletin 37:50-58, 2003.
31. Sangal JM, Sangal RB. Attention-Deficit/Hyperactivity Disorder: Cognitive Evoked Potential (P300) Topography Predicts Treatment Response to Methylphenidate. Clin Neurophysiology, 115:188-193, 2004.
32. Sangal RB, Sangal JM. Rating Scales for Inattention and Sleepiness are Correlated in Adults with symptoms of Sleep Disordered Breathing Syndrome, but not in Adults with symptoms of Attention-Deficit/Hyperactivity Disorder. Sleep Med, 5:133-135, 2004.
33. Wigal S, Swanson JM, Feifel D, Sangal RB, Elia J, Casat CD, Zeldis JB, Conners CK. A Double-Blind, Placebo-Controlled Trial of Dexmethylphenidate Hydrochloride and d,l-threo- Methylphenidate Hydrochloride in children with Attention Deficit Hyperactivity Disorder. J Am Acad Child Adolesc Psychiat, 43:1406-1414, 2004.
34. Arnold LE, Lindsay RL, Conners CK, Wigal SB, Levine AJ, Johnson DE, Scott RA, Sangal RB, Bohan TP, Zeldis JB. A Double-Blind, Placebo-Controlled Withdrawal Trial of Dexmethylphenidate Hydrochloride in Children With Attention Deficit Hyperactivity Disorder. J Child Adolesc Psychopharm, 14:542-554, 2004.
35. Arand D, Bonnet M, Hurwitz T, Mitler M, Rosa R, Sangal RB. The clinical use of the MSLT and MWT. Sleep, 123-144, 2005.
36. Sangal JM, Sangal RB. Attention-Deficit/Hyperactivity Disorder: Cognitive Evoked Potential (P300) Amplitude Predicts Treatment Response to Atomoxetine. Clin Neurophysiology, 116:640-647, 2005.
37. Sangal RB, Owens J, Sangal JM. Patients With Attention-Deficit/Hyperactivity Disorder Without Observed Apneic Episodes in Sleep or Daytime Sleepiness Have Normal Sleep on Polysomnography. Sleep, 28:1128-1133, 2005.
38. Greenhill LL, Beiderman J, Boellner SW, Rugino TA, Sangal RB, Earl CQ, Jiang JG, Swanson JM. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Adolesc Psychiatry, 45:503-511, 2006.
39. Sangal RB. When is Sleepiness a Disease? How do we Measure It? Sleep Medicine, 7:310-311, 2006.
40. Sangal RB, Sangal JM. Attention-Deficit/Hyperactivity Disorder: Use of Cognitive Evoked Potential (P300) To Predict Treatment Response. Clin Neurophysiology, 117:1996-2006, 2006.
41. Sangal RB, Sangal JM. Attention-Deficit/Hyperactivity Disorder: Using P300 Topography to Choose Optimal Treatment. Expert Rev Neurother, 6:1439-1447, 2006.
42. Adler LA, Sutton VK, Moore RJ, Dietrich AP, Reimherr FW, Sangal RB, Saylor KE, Secnik K, Kelsey DK, Allen AJ. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol, 6:648-652, 2006.
43. Newcorn JH, Michelson D, Kratochvil CJ, Allen AJ, Ruff DD, Moore RJ, for the Atomoxetine low-dose study group (incl. Sangal RB). Low-Dose Atomoxetine for Maintenance treatment of Attention-Deficit/Hyperactivity Disorder. Pediatrics, 118:e1701-e1706, 2006.
44. Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D. Effects of Atomoxetine and Methylphenidate on Sleep in Children With ADHD. Sleep, 29:1573-1585, 2006.
45. Spencer T, Kratochvil C, Sangal RB, Saylor K, Bailey C, Dunn D, Geller D, Casat C, Lipetz R, Jain R, Newcorn J, Ruff D, Feldman P, Furr A, Allen AJ. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol, 17:689-699, 2007.
46. Vanhecke TE, Franklin BA, Ajluni SC, Sangal RB, McCullough PA. Cardiorespiratory fitness and sleep-related breathing disorders. Expert Rev Cardiovasc Ther, 6:745-758, 2008.
47. Sangal RB, Sangal JM, Thorp K. Atomoxetine improves Sleepiness and Global Severity of Illness but not the Respiratory Disturbance Index in Mild to Moderate Obstructive Sleep Apnea with Sleepiness. Sleep Medicine, 9:506-510, 2008.
48. Vanhecke TE, Franklin BA, Zalesin KC, Sangal RB, deJong AD, Agrawal V, et al. Cardiorespiratory Fitness and Obstructive Sleep Apnea Syndrome in Morbidly Obese Patients. Chest,134:539-545, 2008.
49. Owens J, Sangal RB, Sutton VK, Bakken R, Allen AA, Kelsey D. Subjective and Objective Measures of Sleep in children with Attention-Deficit/Hyperactivity Disorder. Sleep Medicine, 9: in press, 2008.
Case Reports:
1. Sangal, R. Inhibited Female Orgasm as a Side-Effect of Alprazolam. Am. J. Psychiatry, 142:1223-1224, 1985.
PRESENTATIONS:
Invited and/or refereed international or national meetings:
1. Sangal R, Thomas L. Mean Sleep Latency and Mean Maintenance of Wakefulness. Assoc Prof Sleep Societies, San Diego, 1988.
2. Sangal, R. Multiple Sleep Latency Test and Retest in Narcolepsy. American Med EEG Soc, Lexington, 1988.
3. Sangal R, Thomas L, Mitler MM. Maintenance of Wakefulness Test Versus Multiple Sleep Latency Test: A Factor Analytic Approach. Assoc Prof Sleep Societies, Toronto, 1991.
4. Sangal R Thomas L. Narcolepsy: Improvement in MSLT with Pemoline. Assoc Prof Sleep Societies, Toronto, 1991.
5. Sangal R, Thomas L. Obstructive Sleep Apnea: Improvement in Somnolence with Continuous Positive Airway Pressure. Assoc Prof Sleep Societies, Toronto, 1991.
6. Sangal R, Thomas L. Tests for Measuring Objective Change in Daytime Sleepiness with Treatment. American Electroencephalographic Society, Philadelphia, 1991.
7. Sangal RB, Thomas L, Mitler MM. Disorders of Excessive Sleepiness: Treatment Improves Ability to Stay Awake but Does Not Reduce Sleepiness. Assoc Prof Sleep Societies, Phoenix, 1992.
8. Sangal RB, Sangal JM. Topography of Auditory and Visual P300 in Normal Adults. American EEG Society, New Orleans, 1993.
9. Sangal JM, Sangal RB. Topography of Auditory and Visual P300 in Normal Children. American EEG Society, New Orleans, 1993.
10. Sangal RB., Sangal JM. Severe Daytime Sleepiness causes abnormal Auditory P300 Latency Topography with normal Visual P300 Topography. American EEG Society, New Orleans, 1993.
11. Sangal RB, Sangal JM. Profound Obstructive Sleep Apnea causes abnormal Visual P300 Latency Topography with normal Auditory P300 Topography. American EEG Society, New Orleans, 1993.
12. Sangal RB, Sangal JM. Closed head injuries, excessive daytime sleepiness, and abnormal visual P300 brain topography. Assoc Prof Sleep Societies, Boston, 1994.
13. Sangal RB, Sangal JM. P300 brain topography is differentially affected by somnolence of different types. Assoc Prof Sleep Societies, Boston, 1994.
14. Sangal RB, Sangal JM. Sleep apnea impairs visual cognitive function as measured by P300 brain topography. Assoc Prof Sleep Societies, Boston, 1994.
15. Sangal RB, Sangal JM. Measures of sleepiness (maintenance of wakefulness test and multiple sleep latency test) and P300 amplitudes and latencies measure different abilities in patients with sleep disorders. Assoc Prof Sleep Societies, Boston, 1994.
16. Sangal JM., Sangal RB, Persky B. P300 Topography predicts treatment response in attention deficit disorder. American EEG Society, Chicago, 1994.
17. Sangal RB, Sangal JM. P300 Latency: Abnormal in Sleep Apnea with Somnolence and Idiopathic Hypersomnia, but Normal in Narcolepsy. American Psychiatry Electrophysiology Association, Miami, 1995.
18. Sangal RB, Semery JP., Belisle C. Computerized Analysis of Abnormal Human Sleep offers Reasonable Results. Assoc Prof Sleep Societies, Washington, 1996.
19. Sangal RB, Sangal JM, Belisle C. MWT and ESS Measure Different Abilities in 41 Patients with Snoring and Daytime Sleepiness. Assoc Prof Sleep Societies, San Francisco, 1997.
20. Sangal RB, Mitler MM, Sangal JM., US Modafinil in Narcolepsy Study Group. MSLT, MWT and ESS: Indices of Sleepiness in 522 Drug-free Patients with Narcolepsy. Assoc Prof Sleep Societies, San Francisco, 1997.
21. Mitler MM, Walsleben J, Sangal RB. US Modafinil in Narcolepsy Study Group. MWT Sleep Latencies for 530 Drug-Free Patients with Narcolepsy. Assoc Prof Sleep Societies, San Francisco, 1997.
22. Sangal RB, Sangal JM, Belisle C. Patients with Narcolepsy have longer Auditory and Visual P300 Latencies. Assoc Prof Sleep Societies, New Orleans, 1998.
23. Sangal RB, Sangal,JM, Belisle C. P300 Measures in Narcolepsy predict Treatment Response to Modafinil. Assoc Prof Sleep Societies, New Orleans, 1998.
24. Sangal,RB, Sangal JM,., Belisle C. Predicting Treatment Response in Narcolepsy using the P300. International Society for Brain Electromagnetic Topography/ EEG and Clinical Neuroscience Society, New Orleans, 1998.
25. Sangal,RB. Cognitive Evoked Potentials (P300 Topography) in the Treatment of Attention Deficit. EEG and Clinical Neuroscience Society, Macon, 2000.
26. Sangal RB, Sangal JM, Ollila M. Rating Scales for Inattention and Sleepiness are correlated in Sleep Disordered Patients, but not in Patients with Attention Deficit-Hyperactivity Disorder. Assoc Prof Sleep Societies, Chicago, 2001.
27. Sangal RB, Sangal JM, Ollila M. Polysomnograhic Evidence of Normal Sleep Related Respiration in Patients with Attention Deficit-Hyperactivity Disorder. Assoc Prof Sleep Societies, Seattle, 2002.
28. Sangal RB, Sangal JM. The Epworth Sleepiness Scale Does Not Measure Perceived Sleepiness in Patients with Sleep Apnea. Assoc Prof Sleep Societies, Chicago, 2003.
29. Sangal RB, Sangal JM. Patients with Attention Deficit Hyperactivity Disorder Have Normal Sleep on Polysomnography. Assoc Prof Sleep Societies, Chicago, 2003.
30. Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Feng MS, Kelsey D. Effects of Atomoxetine and Methylphenidate on Sleep in Children with ADHD. Assoc Prof Sleep Societies, Philadelphia, 2004.